STING1 and breast cancer: Both in vitro and in vivo experiments showed that PDT with PNBS/DiABZI effectively destroyed hypoxic tumors and facilitated the proliferation of CTLs and NK cells, overcoming resistance linked to reduced NK cell proliferation observed with STING agonist monotherapy.[117] Remarkably, a single intravenous dose of PNBS/diABZI nanovesicles completely eliminated orthotopic mammary tumors in mice under laser irradiation, induced long‐lasting antitumor immune memory, and conferred resistance to subcutaneous or intravenous tumor rechallenge with 4T1 cells.